Finding ways to improve immunotherapy for lung cancer patients with STK11 mutations
Official title: Biomarker-Driven Strategies to Overcome Immunotherapy Resistance in STK11-Deficient NSCLC
Funded at Ohio State University · NIH-10887315 · Data updated 2026-11-12
This study is looking at how certain features of lung cancer in patients with STK11 mutations can influence how well they respond to immunotherapy, with the hope of finding better ways to help those who struggle with current treatments.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project start | September 2, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $281,370 |
| NIH project number | 1K08CA279925-01A1 |
| Project ID | NIH-10887315 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are lung cancer patients who have been diagnosed with STK11-deficient tumors.
✕Less likely to help
Patients with lung cancer who do not have STK11 mutations may not benefit from this research.
What this research studies
This research investigates how specific tumor characteristics in lung cancer patients with STK11 mutations affect their response to immunotherapy. By studying the tumor microenvironment and identifying new biomarkers, the team aims to understand why some patients do not respond to current treatments. They will validate a novel biomarker called STK11-MLDD to predict which patients might benefit from immunotherapy. The research also explores the role of certain immune regulators in promoting resistance to treatment, with the goal of developing more effective strategies for these patients.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for lung cancer patients with STK11 mutations, enhancing their chances of responding to immunotherapy.
How similar studies have gone: Previous research has shown promise in using biomarkers to predict responses to immunotherapy, making this approach both relevant and potentially impactful.
Where this research is happening
-
Ohio State University
Columbus, United States Active
Researchers
- Principal investigator: Kaufman, Jacob Marcus — Ohio State University
- Study coordinator: Kaufman, Jacob Marcus
Related research
Other NIH-funded projects on the same topics.
-
Biomarker-driven approach to overcome immune resistance in STK11-deficient NSCLC
A doctor-led program aims to use a new biomarker to guide immunotherapy for a common type of lung cancer that often resists treatment.
-
Improving Immunotherapy for Lung Cancer with CT Scans
This work aims to find new ways to predict which non-small cell lung cancer patients will respond best to immunotherapy using information from their routine CT scans.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.